Form 4: Verve Therapeutics Director Michael MacLean Acquires Stock Options

Director Michael MacLean acquired stock options in Verve Therapeutics, Inc. on June 26, 2024, as part of the company's director compensation program.

Summary

• Michael F MacLean, a director of Verve Therapeutics, Inc., acquired stock options on June 26, 2024.
• The stock options grant the right to buy 136,139 shares of common stock at an exercise price of $5.02.
• These options were issued under the 2021 Stock Incentive Plan as part of the director compensation program.
• The options vest upon the earlier of one year from the grant date or immediately before the first annual meeting of stockholders after the grant date, contingent on continued service as a director.
• Following the transaction, MacLean directly owns derivative securities consisting of 136,139 stock options.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing a standard compensation practice. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, aligning their interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary significantly across the biotechnology industry depending on company size, stage of development, and board responsibilities.
• Comparing Verve Therapeutics' director compensation to peers like CRISPR Therapeutics, Editas Medicine, or Intellia Therapeutics would provide a benchmark for assessing the competitiveness and appropriateness of the grant.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's actions lead to improved company performance.
• The grant provides an incentive for the director to act in the best interests of the company and its stakeholders.

Key Dates